Associations of alternative cannabis product use and poly-use with subsequent illicit drug use initiation during adolescence.

Adolescents Cannabis Edible Poly-substance use Vaping

Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
03 Mar 2023
Historique:
received: 05 08 2020
accepted: 28 01 2023
pmc-release: 03 09 2024
entrez: 2 3 2023
pubmed: 3 3 2023
medline: 3 3 2023
Statut: aheadofprint

Résumé

Specific cannabis products may differentially increase risk of initiating non-cannabis illicit drug use during adolescence. To determine whether ever- and poly-use of smoked, vaporized, edible, concentrate, or blunt cannabis products are associated with subsequent initiation of non-cannabis illicit drug use. High school students from Los Angeles completed in-classroom surveys. The analytic sample (N = 2163; 53.9% female; 43.5% Hispanic/Latino; baseline M age = 17.1 years) included students who reported never using illicit drugs at baseline (spring, 11th grade) and provided data at follow-up (fall and spring, 12th grade). Logistic regression models assessed associations between use of smoked, vaporized, edible, concentrate, and blunt cannabis at baseline (yes/no for each product) and any non-cannabis illicit drug use initiation-including cocaine, methamphetamine, psychedelics, ecstasy, heroin, prescription opioids, or benzodiazepines-at follow-up. Among those who never used non-cannabis illicit drugs at baseline, ever cannabis use varied by cannabis product (smoked = 25.8%, edible = 17.5%, vaporized = 8.4%, concentrates = 3.9%, and blunts = 18.2%) and patterns of use (single product use = 8.2% and poly-product use = 21.8%). After adjustment for baseline covariates, odds of illicit drug use at follow-up were largest for baseline ever users of concentrates (aOR [95% CI] = 5.74[3.16-10.43]), followed by vaporized (aOR [95% CI] = 3.11 [2.41-4.01]), edibles (aOR [95% CI] = 3.43 [2.32-5.08]), blunts (aOR [95% CI] = 2.66[1.60-4.41]), and smoked (aOR [95% CI] = 2.57 [1.64-4.02]) cannabis. Ever use of a single product (aOR [95% CI] = 2.34 [1.26-4.34]) or 2 + products (aOR [95% CI] = 3.82 [2.73-5.35]) were also associated with greater odds of illicit drug initiation. For each of five different cannabis products, cannabis use was associated with greater odds of subsequent illicit drug use initiation, especially for cannabis concentrate and poly-product use.

Identifiants

pubmed: 36864260
doi: 10.1007/s00213-023-06330-w
pii: 10.1007/s00213-023-06330-w
pmc: PMC10475141
mid: NIHMS1911606
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA042950
Pays : United States
Organisme : NCI NIH HHS
ID : K24DA048160
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA048160
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229617
Pays : United States
Organisme : NIMH NIH HHS
ID : 5T32MH109436-03
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA229617
Pays : United States
Organisme : NIDA NIH HHS
ID : K01DA042950-01
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Drug Alcohol Depend. 2015 Oct 1;155:307-11
pubmed: 26338481
Addict Behav. 2017 Nov;74:41-47
pubmed: 28570913
Subst Use Misuse. 2018 Mar 21;53(4):654-661
pubmed: 28933976
Addiction. 2017 Dec;112(12):2182-2190
pubmed: 28623880
Curr Opin Psychol. 2019 Dec;30:98-102
pubmed: 31071592
J Stud Alcohol Drugs. 2007 Mar;68(2):256-65
pubmed: 17286344
Drug Alcohol Depend. 2008 May 1;95(1-2):1-13
pubmed: 18242006
J Stud Alcohol Drugs. 2011 Mar;72(2):279-85
pubmed: 21388601
Ann Med. 2000 Sep;32(6):401-7
pubmed: 11028688
JAMA Netw Open. 2018 Sep 7;1(5):e182765
pubmed: 30646180
Drug Alcohol Depend. 2019 Jan 1;194:51-58
pubmed: 30399500
J Res Adolesc. 2014 Dec 1;24(4):630-645
pubmed: 25506186
Clin EEG Neurosci. 2009 Jan;40(1):31-8
pubmed: 19278130
Addict Behav. 2009 Mar;34(3):319-22
pubmed: 19022584
Drug Alcohol Depend. 2018 May 1;186:68-74
pubmed: 29550624
Drug Alcohol Depend. 2020 Jan 1;206:107716
pubmed: 31718923
Addiction. 2006 Apr;101(4):556-69
pubmed: 16548935
Subst Abuse. 2017 Sep 25;11:1178221817733736
pubmed: 28979131
J Consult Clin Psychol. 2000 Feb;68(1):19-30
pubmed: 10710837
Addict Behav. 2015 Feb;41:218-22
pubmed: 25452068
J Addict Dis. 1992;11(3):47-61
pubmed: 1627666
JAMA Pediatr. 2019 Sep 01;173(9):e191750
pubmed: 31282942
Psychol Med. 2016 Mar;46(4):841-54
pubmed: 26610039
Prev Med. 2011 Jun;52(6):475-6
pubmed: 21443900
Nicotine Tob Res. 2018 Feb 7;20(3):370-376
pubmed: 28003508
NCHS Data Brief. 2017 Aug;(282):1-8
pubmed: 29155681
Drug Alcohol Depend. 2020 Apr 1;209:107900
pubmed: 32061947
J Pediatr Psychol. 2001 Jul-Aug;26(5):287-98
pubmed: 11390571
J Adolesc Health. 2019 Apr;64(4):487-493
pubmed: 30205931
J Prim Prev. 2016 Jun;37(3):303-9
pubmed: 27056685
Drug Alcohol Depend. 2019 Jul 1;200:40-49
pubmed: 31085377
Pain Med. 2014 Oct;15(10):1765-70
pubmed: 25139712
Subst Use Misuse. 2006;41(1):103-55
pubmed: 16393739

Auteurs

Jessica L Braymiller (JL)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.

Kira E Riehm (KE)

Department of Mental Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, 21205, USA.

Madeline Meier (M)

Department of Psychology, Arizona State University, Tempe, AZ, 85281, USA.

Evan A Krueger (EA)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.

Jennifer B Unger (JB)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.

Jessica L Barrington-Trimis (JL)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.
Institute for Addiction Science, University of Southern California, 2001 N Soto Street, #302-C, Los Angeles, CA, 90032, USA.
USC Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.

Junhan Cho (J)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.
Institute for Addiction Science, University of Southern California, 2001 N Soto Street, #302-C, Los Angeles, CA, 90032, USA.

H Isabella Lanza (HI)

Department of Human Development, California State University, Long Beach, CA, 90840, USA.

Danielle R Madden (DR)

Institute for Addiction Science, University of Southern California, 2001 N Soto Street, #302-C, Los Angeles, CA, 90032, USA.
USC Suzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA, 90089, USA.

Afton Kechter (A)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA.

Adam M Leventhal (AM)

Department of Population and Public Health Sciences, University of Southern California, Keck School of Medicine, Los Angeles, CA, 90033, USA. adam.leventhal@usc.edu.
Institute for Addiction Science, University of Southern California, 2001 N Soto Street, #302-C, Los Angeles, CA, 90032, USA. adam.leventhal@usc.edu.
USC Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA. adam.leventhal@usc.edu.
Department of Psychology, University of Southern California, Los Angeles, CA, 90033, USA. adam.leventhal@usc.edu.

Classifications MeSH